Connect your AI

CRISPR Therapeutics CRSP Other liabilities

Other liabilities at other companies

Schneider NationalSNDR

$17.6M+296%

LKQLKQ

$75M+500%

Ondas, Inc. ONDS

$13K—

CHE

ChemedCHE

$6.71M+605%

PopularBPOP

-$86.06M-125%

EAT

Brinker InternationalEAT

$700K-78.8%

Other financials

Income statement

Revenue$1.5M+68.6%

Operating income-$130.2M+12.2%

Net income-$122.9M+9.6%

EPS (diluted)-$1.28+19.0%

Balance sheet

Cash & equivalents$423.3M+80.0%

Total debt$787.6M+259%

Total equity$1.8B-0.8%

Total assets$2.7B+25.8%

Cash flow

Operating cash flow-$108.9M-102%

CapEx$504.0K+145%

Free cash flow-$109.4M-102%

Valuation

Market cap$5.33B+56.4%

Enterprise value$5.69B+69.8%

P/S1,298.3×+1,208×

Profitability

Operating margin-15,754.2%-17,253pp

Net margin-13,856.5%-15,058pp

FCF margin-9,777.6%-10,759pp

Returns & leverage

Return on equity-31.2%+43.7pp

Debt / equity0.4×+0.3×

Current ratio18×+2.3×

Where this comes from

Reported directly by CRISPR Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherOperatingLiabilities.

The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about CRISPR Therapeutics's other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is CRISPR Therapeutics's other liabilities?: CRISPR Therapeutics (CRSP) reported other liabilities of -$199K in Q1 2026.
How has CRISPR Therapeutics's other liabilities changed year-over-year?: CRISPR Therapeutics's other liabilities increased by 98.1% year-over-year, from -$10.54M to -$199K.